Scientists have identified genetic features in immune cells that may indicate the onset of multiple sclerosis (MS) years before symptoms appear. This discovery could lead to earlier diagnoses, more targeted treatments, and potentially prevent or delay the debilitating effects of the disease.
Shares of Denali Therapeutics (DNLI) dropped significantly in after-hours trading following the news that its Phase 2 study of oditrasertib for multiple sclerosis was discontinued due to failure to meet primary and secondary endpoints. The company is expected to provide further details on the study’s termination during its upcoming earnings call.
Sanofi’s experimental drug tolebrutinib has shown positive results in a Phase 3 study for non-relapsing secondary progressive multiple sclerosis (nrSPMS), demonstrating a delay in disability progression compared to placebo. While previous studies on relapsing forms of MS did not meet the primary endpoint, the latest findings suggest tolebrutinib’s potential as a treatment option for secondary progressive MS.
Novartis’ Kesimpta (ofatumumab) demonstrated sustained efficacy in treating relapsing multiple sclerosis (RMS) for up to six years, leading to less disability and disease progression compared to switching from Aubagio (teriflunomide). This data was presented at the European Committee for Treatment and Research in Multiple Sclerosis. The FDA also approved Novartis’ Kisqali (ribociclib) for adjuvant treatment of high-risk early breast cancer.
TG Therapeutics, Inc. (TGTX) saw its stock climb on Wednesday after presenting updated data from its Phase 3 trials for BRIUMVI (ublituximab-xiiy), a potential treatment for relapsing forms of multiple sclerosis. The data, shared at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, showed sustained clinical benefits with continued use of BRIUMVI, including reduced relapse rates and a low rate of disability progression.
New data from the Daybreak trial shows that Zeposia (ozanimod), a treatment for relapsing forms of multiple sclerosis, effectively reduced brain volume loss in patients for up to five years. The study also demonstrated a declining incidence of treatment-related adverse events over an extended period, suggesting a favorable safety profile for the drug.
Adia Nutrition has appointed Dr. Richard Edwards as its second Medical Director, joining Dr. Monica Sher to form a diverse and highly experienced board. This strategic move signifies the company’s commitment to providing exceptional care and advancing innovative aHSCT treatments for patients with Multiple Sclerosis (MS).
Sanofi’s experimental drug, tolebrutinib, has shown positive results in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). While the drug did not meet the primary endpoint in relapsing forms of MS, secondary data showed a significant delay in disability worsening. However, concerns regarding potential liver damage and effectiveness remain, impacting the drug’s revenue prospects.
A 26-year-old woman shares her journey of being diagnosed with multiple sclerosis, highlighting the importance of early detection and timely treatment. The story underscores the need to pay attention to seemingly minor symptoms and seek medical advice immediately, as early intervention can significantly impact quality of life.
Christina Applegate has revealed that she wears diapers due to a severe stomach bug she contracted from eating a tainted salad. The sapovirus infection caused intense symptoms, including dizziness, nausea, and vomiting. Despite her battle with multiple sclerosis, Applegate’s condition worsens the situation, making it challenging to reach the bathroom in time. Co-host Jamie-Lynn Sigler empathized, acknowledging that similar issues are common among those with MS.
